EXAS

$EXAS chatter on StockTwits

• 
  Krish@kd777994d

  $EXAS

  View on StockTwits ↗
• 
  M p@doc123266Jul 27

  $GLSI $EXAS was bought for $21B. It’s a box you poop in to test for colon cancer. Think about it a box and a test. $20B. Save lives ? Yes. Early detection critical. vs. An actual treatment to save lives once disease has occurred. I feel like the value of this treatment would outweigh monetarily the value of a diagnostic. One for which we already have methods of detection. In the US breast cancer is nearly double that of colon. BTW 5% colon cancers are her2. Beating a dead horse but Snehal has suggested glsi-100 could be used for other her2 cancers.

  View on StockTwits ↗
• 
  🐺 WOLFIE@WOLFSTREETJul 21

  @Gallium7 @LukaWo @OneFryShy I do "ZERO" research so would not know, I use CC to handle investment trades. I too had a great profit margin with $EXAS , same $ROKU all posted here before and after. With $PSNL in at 3 and hitting 16 is about as good as it gets with "ZERO" effort. This is what CC does for me, provides "CALM CONFIDENCE" to allocate accordingly and achieve optimal results.

  View on StockTwits ↗
• 
  thingkfast@thingkfastJul 16

  $EXAS I don’t think $ABT overpaid

  View on StockTwits ↗
• 
  Full Name@KappaKeepoKuppoJul 16

  $ABT calm down guys, the entire market is down. When the market turns upwards, this will extend the pump too. I think today’s earnings call changed the narrative of this company for good, especially in terms of clearing the doubt that they overpaid for $EXAS acquisition

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJul 15

  A blood-cancer diagnostics market worth roughly $500 million in the US sits largely untapped, and Precipio, Inc. (Nasdaq: $PRPO ) intends to scale into it without much added cost. Danieli used his Planet MicroCap Las Vegas 2026 slot to map the runway, from current production capacity to a long-term shift in the company's revenue mix. Precipio, Inc. - Nasdaq: PRPO is a B2i Digital Featured Company. See the company's profile at b2idigital.com/precipio-inc-1 and follow Precipio on X, LinkedIn, and Facebook. "On the product side, we currently have capacity to produce about $50 million of product annually," said Danieli. "We did three last year, so plenty of room to grow with no further investment. And if we had to go beyond that, if we had to double that capacity, it's about $700,000 to double our capacity from 50 million to 100 million. So extremely scalable in our business." Beyond the numbers, Danieli walked through: • A blood-cancer diagnostics market of roughly $500 million in the US, with Precipio's tests covering about 85% of blood cancer diseases • A planned shift in revenue mix from about 90% laboratory services and 10% products today toward 60/40, with products carrying roughly 80% margins • Longer-term plans to extend the same model into solid tumors and molecular tests beyond cancer Watch the full presentation: https://youtu.be/xX88-sWtszM Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address the problem of cancer misdiagnoses by developing diagnostic products and services designed to deliver greater accuracy, improved laboratory workflow, and better patient outcomes. Precipio develops, validates, and clinically uses these technologies in its laboratory before commercializing them as proprietary products for the global laboratory community. More information is at precipiodx.com. Investor inquiries: investors@precipiodx.com, +1-203-787-7888 Ext. 523. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: This post is informational only and is not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. $EXAS, $NTRA, $GH, $XBI

  View on StockTwits ↗
• 
  Enjoy Life@Enjoy_Life_BroJul 14

  $ABT No one is expecting earnings to be positive after the recent overpriced acquisition. It is going to take years to recover. $EXAS took them to the cleaners on that acquisition and most investors will not be forgiving

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJul 8

  $EXAS, $NTRA, $GH, $XBI

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJul 2

  Profitable as of Q3 2025, Precipio (Nasdaq: $PRPO ) has canceled its ATM facility to move away from the dilutive capital raises common among microcap companies. Precipio, Inc. (Nasdaq: PRPO) did something uncommon for a microcap diagnostics company: it turned profitable, hitting that mark in the third quarter of 2025 and canceling the at-the-market facility it once leaned on. CEO Ilan Danieli framed the shift for microcap investors as a deliberate move toward financial independence. Precipio is a B2i Digital Featured Company. See the company's profile at b2idigital.com/precipio-inc-1 and follow Precipio on X, LinkedIn, and Facebook. "One of the most important things for us as a company to achieve in 2025 was to become profitable," said Danieli. "A couple years ago we did a capital raise. It wasn't the prettiest one, and our team sat around and said, that's it, we're done, we're not doing anything more. We're going to become financially independent. And we did. So we are profitable as of Q3 of 2025." Elsewhere in the session, Danieli covered: • That Precipio canceled its at-the-market (ATM) facility, a signal to shareholders that it would stop the dilutive financing many microcaps rely on • How a cash-efficient model lets the company fund new products without raising another $5 million and diluting investors each time • Why he believes operating profitably at the company's current scale makes for an attractive long-term business model Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address the problem of cancer misdiagnoses by developing diagnostic products and services designed to deliver greater accuracy, improved laboratory workflow, and better patient outcomes. Precipio develops, validates, and clinically uses these technologies in its laboratory before commercializing them as proprietary products for the global laboratory community. More information is at precipiodx.com. Investor inquiries: investors@precipiodx.com, +1-203-787-7888 Ext. 523. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: This post is informational only and is not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. $EXAS, $NTRA, $GH, $XBI

  View on StockTwits ↗
• 
  Christopher Hromada@Chromada06Jul 1

  $GH just took 300% on my initial investment from 10/2024 … sold 43% of my position. On top of doing really well with $EXAS earlier this year… colonoscopy inspired these investments. 🍾

  View on StockTwits ↗
• 
  David Shapiro@B2iDigitalJun 16

  Phio Pharmaceuticals Corp. PH-762 silences PD-1 inside a tumor to help the immune system attack cancer. Robert Bitterman, President and CEO of Phio Pharmaceuticals Corp. (NASDAQ: $PHIO ), used a Force Family Office webinar to explain how the company's lead candidate, PH-762, works. The drug targets PD-1, a protein that tumors use to switch off the immune system's T cells, by silencing the gene that produces it so those T cells can recognize the tumor and attack it. Phio Pharmaceuticals Corp. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/phio-pharmaceuticals Bitterman walked through what happens once PH-762 is injected: "...what we do is we're turning off the signal from the gene that's producing the protein, the PD-1. In the absence of PD-1, the T-cells have the ability to basically recover, to reinvigorate, and to go about recognizing the tumor and attack it, which is what a normal healthy immune system will do to a foreign invader." The webinar also covered: • PH-762 as a short interfering RNA (siRNA) injected directly into a tumor, part of Phio's INTASYL® platform • How silencing PD-1 is designed to reinvigorate T cells so they recognize and attack the tumor • Dr. Mary Spellman's point that treating locally right at the lesion and may mean fewer systemic side effects • Bitterman's comparison of the approach to shutting off a water faucet at its source Watch the full presentation: https://youtu.be/QTVd5xDCgGE Phio Pharmaceuticals is a clinical stage biotechnology company developing immuno oncology therapeutics using its INTASYL® self delivering RNAi platform, led by President and CEO Robert Bitterman. Its lead candidate, PH-762, silences designated genes to make immune cells more effective against cancer cells. Learn more at https://phiopharma.com. For investor information, visit https://phiopharma.com/investors/. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $EXAS, $NTRA, $GH, $XBI

  View on StockTwits ↗
• 
  Steve@Woodman7Jun 12

  @dmc4321 @oaksapollo - I was a longtime $EXAS fan and loved the company and the stock. It was my #1 holding for years and I bought all the dips along the way. Even though I made a lot of money off the stock and hundreds of calls I had at the time I was disappointed when they sold to $ABT because I wanted to see them more fully achieve their destiny as a stand alone company/stock. However, I say all this just to say that you never know what will happen. Value is value. It WILL bubble to the surface. Exact grew to a point where the logical next step was to merge with a much larger player that could use its reach and resources to take it to an even greater place. How the value of $LUCD gets monetized is TBD at this point. But it does have great value imho, esp vs the current market price. They may not have to slug it out for years to get traction and scale. They may simply partner up, sell rights, merge, get taken private, etc…But one way or another, the value will emerge.

  View on StockTwits ↗
• 
  julian jakobi@julianjakobiBullishJun 5

  $BLGO Why I own 1.25% of $BLGO - full DD (link below) Wrote this for family after a long discussion with a retired doctor about why I keep adding despite weak sentiment. I recently added another $40K. This isn’t hype-it’s conviction built over years of research, criticism, and experience. I’ve seen setups like this before ($EXAS From multi year lows → 2000%+), where the story looked worst before it works. BioLargo, in my view, is deeply misunderstood. Clean water, clean air, advanced wound care, lithium-free batteries-real problems, real tech. The best opportunities are uncomfortable, unpopular, and doubted. That’s exactly why I’m here. TL;DR: will be here until the whole success story will have unfolded. We know what is coming. IMHO a screaming strong buy at $36 Million Market Cap. Safe download link to Full 26 pages DD: https://drive.google.com/file/d/133fUlR-Mu_SXFzdthMuSeE_7ZPPkm1_q/view

  View on StockTwits ↗
• 
  Lynker@GordoHLYK13May 20

  $NEO Back in 2018 I held 1k shares of NeoGenomics at a $13 average and watched it run to $60. Fast forward to 2026… now I’m holding 4k shares at $8.56 and the setup honestly looks even stronger. NEO today isn’t the same company from 2018 — bigger revenue, deeper oncology relationships, more advanced molecular testing, AI-driven diagnostics, and expanding precision medicine exposure. While everyone chases hype, NEO is quietly building a real cancer diagnostics powerhouse. The business is making substantially more money than it was during the last major run, yet the stock trades at a fraction of those levels. If execution keeps improving and margins expand, this could easily feel like NeoGenomics 4.0. 🚀 $NEO making way more money than the 2018 run to $60… yet trading near $8. Different beast now — stronger tech, bigger oncology footprint, AI diagnostics growth, and huge upside if sentiment flips. NeoGenomics 4.0 loading. 🔥 $TEM $NTRA $GH $EXAS

  View on StockTwits ↗
• 
  William S Burroughs@DoctrBenwayBullishMay 12

  $GERN Uptake takes time. Stay long and the numbers continually become more compelling as hematologists (prone to inertia until something is proven compellingly better) change their practice in MDS/MF. Analogy: I knew Cologuard would have uptake and bought tons of $EXAS in the $4 range, I knew low risk patients would eschew a prep and procedure once the diagnostic follow-up was covered.

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.